BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11511720)

  • 1. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?
    Kapaki E; Kilidireas K; Paraskevas GP; Michalopoulou M; Patsouris E
    J Neurol Neurosurg Psychiatry; 2001 Sep; 71(3):401-3. PubMed ID: 11511720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants.
    Abu Rumeileh S; Lattanzio F; Stanzani Maserati M; Rizzi R; Capellari S; Parchi P
    J Alzheimers Dis; 2017; 55(4):1471-1480. PubMed ID: 27886009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prion-specific and surrogate CSF biomarkers in Creutzfeldt-Jakob disease: diagnostic accuracy in relation to molecular subtypes and analysis of neuropathological correlates of p-tau and Aβ42 levels.
    Lattanzio F; Abu-Rumeileh S; Franceschini A; Kai H; Amore G; Poggiolini I; Rossi M; Baiardi S; McGuire L; Ladogana A; Pocchiari M; Green A; Capellari S; Parchi P
    Acta Neuropathol; 2017 Apr; 133(4):559-578. PubMed ID: 28205010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tau protein as a marker for the diagnosis of Creutzfeldt-Jakob disease.
    Noguchi-Shinohara M; Hamaguchi T; Nozaki I; Sakai K; Yamada M
    J Neurol; 2011 Aug; 258(8):1464-8. PubMed ID: 21360196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: over 10-Year Period Review.
    Koscova S; Zakova Slivarichova D; Tomeckova I; Melicherova K; Stelzer M; Janakova A; Kosorinova D; Belay G; Mitrova E
    Mol Neurobiol; 2017 Oct; 54(8):5919-5927. PubMed ID: 27665282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease.
    Kapaki EN; Paraskevas GP; Tzerakis NG; Sfagos C; Seretis A; Kararizou E; Vassilopoulos D
    Eur J Neurol; 2007 Feb; 14(2):168-73. PubMed ID: 17250725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt-Jakob disease and autoimmune encephalitis.
    Chang BK; Day GS; Graff-Radford J; McKeon A; Flanagan EP; Algeciras-Schimnich A; Mielke MM; Nguyen A; Jones DT; Toledano M; Kremers WK; Knopman DS; Petersen RC; Li W
    Eur J Neurol; 2022 Oct; 29(10):2905-2912. PubMed ID: 35735602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia.
    Karch A; Llorens F; Schmitz M; Arora AS; Zafar S; Lange P; Schmidt C; Zerr I
    J Alzheimers Dis; 2016 Oct; 54(4):1385-1393. PubMed ID: 27589519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.
    Grangeon L; Paquet C; Bombois S; Quillard-Muraine M; Martinaud O; Bourre B; Lefaucheur R; Nicolas G; Dumurgier J; Gerardin E; Jan M; Laplanche JL; Peoc'h K; Hugon J; Pasquier F; Maltête D; Hannequin D; Wallon D;
    J Alzheimers Dis; 2016; 51(3):905-13. PubMed ID: 26890785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease.
    Sorensen KC; Simonsen AH; Holmetoft UB; Hasselbalch SG; Heegaard NH
    J Alzheimers Dis; 2013; 37(2):379-87. PubMed ID: 23948879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer's Disease.
    Hermann P; Haller P; Goebel S; Bunck T; Schmidt C; Wiltfang J; Zerr I
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.
    Blennow K; Diaz-Lucena D; Zetterberg H; Villar-Pique A; Karch A; Vidal E; Hermann P; Schmitz M; Ferrer Abizanda I; Zerr I; Llorens F
    J Neurol Neurosurg Psychiatry; 2019 Aug; 90(8):846-853. PubMed ID: 31097472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease.
    Green AJ
    Neuropathol Appl Neurobiol; 2002 Dec; 28(6):427-40. PubMed ID: 12445159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease.
    Buerger K; Otto M; Teipel SJ; Zinkowski R; Blennow K; DeBernardis J; Kerkman D; Schröder J; Schönknecht P; Cepek L; McCulloch C; Möller HJ; Wiltfang J; Kretzschmar H; Hampel H
    Neurobiol Aging; 2006 Jan; 27(1):10-5. PubMed ID: 16298235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteinase-activated receptor 2 and disease biomarkers in cerebrospinal fluid in cases with autopsy-confirmed prion diseases and other neurodegenerative diseases.
    Rohan Z; Smetakova M; Kukal J; Rusina R; Matej R
    BMC Neurol; 2015 Mar; 15():50. PubMed ID: 25886404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias.
    Riemenschneider M; Wagenpfeil S; Vanderstichele H; Otto M; Wiltfang J; Kretzschmar H; Vanmechelen E; Förstl H; Kurz A
    Mol Psychiatry; 2003 Mar; 8(3):343-7. PubMed ID: 12660807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease.
    Van Everbroeck B; Quoilin S; Boons J; Martin JJ; Cras P
    J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1210-4. PubMed ID: 12933920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.
    Llorens F; Kruse N; Schmitz M; Shafiq M; da Cunha JE; Gotzman N; Zafar S; Thune K; de Oliveira JR; Mollenhauer B; Zerr I
    J Neurol; 2015 Oct; 262(10):2305-11. PubMed ID: 26162713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease.
    Dorey A; Tholance Y; Vighetto A; Perret-Liaudet A; Lachman I; Krolak-Salmon P; Wagner U; Struyfs H; De Deyn PP; El-Moualij B; Zorzi W; Meyronet D; Streichenberger N; Engelborghs S; Kovacs GG; Quadrio I
    JAMA Neurol; 2015 Mar; 72(3):267-75. PubMed ID: 25559883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity and specificity evaluation of multiple neurodegenerative proteins for Creutzfeldt-Jakob disease diagnosis using a deep-learning approach.
    Lee SM; Hyeon JW; Kim SJ; Kim H; Noh R; Kim S; Lee YS; Kim SY
    Prion; 2019 Jan; 13(1):141-150. PubMed ID: 31306078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.